Clin2
NCT06940102Possibly a fitRecruiting

A study on megestrol acetate for weight loss in advanced digestive cancer

CachexiaDigestive System CancerGastric CancerColorectal CancerHepatocellular Carcinoma

Treatments studied

Part of Cancer, Digestive system clinical trials.

This study tests a special form of megestrol acetate (a medicine that can help with appetite and weight gain) in people with advanced digestive system cancers who are about to start or are already taking a type of targeted therapy called a TKI. The goal is to see if it helps with cancer-related weight loss and wasting (cachexia).

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
120 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You must be 18 years or older.
  • You have an advanced digestive system cancer that cannot be cured with surgery or other local treatments.
  • You are scheduled to receive or are currently receiving a TKI-based cancer treatment (possibly with chemotherapy or immunotherapy).
  • You have been diagnosed with pre-cachexia or cachexia (unintentional weight loss and muscle wasting related to your cancer).
  • You are able to take care of yourself (ECOG score 0–2) and your doctor expects you to live at least 3 more months.
  • You do not have a bowel blockage, severe heart/kidney/liver disease, or a major surgery in the last month.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07356037Not yet recruiting· Phase 3
Nanocrystalline megestrol acetate for liver cancer wasting

This trial tests a drug called nanocrystalline megestrol acetate to help people with advanced liver cancer who are losing weight and muscle mass. It's for those who have not yet had systemic therapy and are receiving other cancer treatments at the same time.

Chengdu, Sichuan
NCT07565415Not yet recruiting· Phase 2
Appetite Booster for Liver Cancer With Weight Loss

This trial tests whether a medication called megestrol acetate can help improve appetite and prevent weight loss in patients with advanced liver cancer who are receiving combination cancer treatment. The study compares the medication to placebo (inactive pill) to see if it helps patients feel hungrier and maintain their weight during treatment.

Guangzhou, Guangdong
NCT07338487Recruiting· Phase 1
Nanocrystalline megestrol acetate with chemoradiation for advanced cervical cancer

This trial tests a newer form of megestrol acetate (a medication that can help with appetite and weight) given alongside standard chemotherapy and radiation for locally advanced cervical cancer that cannot be removed by surgery. The study aims to see if this combination is safe and effective.

Changsha, Hunan
NCT06830018Recruiting
New megestrol for advanced stomach or colon cancer with fatigue

This study tests a new form of megestrol (a medicine that can boost appetite and energy) for people with advanced stomach or colorectal cancer who also have fatigue and poor appetite. It is given as a first treatment, meaning you haven't had chemotherapy yet for your advanced cancer.

Shenyang, Liaoning
NCT07243379Recruiting· Phase 4
Studying nanocrystalline megestrol acetate for weight loss in cancer

This study tests a special form of the drug megestrol acetate (Megace) in cancer patients who have lost weight and appetite (cachexia). It aims to see if this medication can help improve weight gain and quality of life.

Zhengzhou, Henan
NCT06998758Recruiting· Phase 3
Megestrol Acetate for weight loss during chemo in advanced colorectal cancer

This trial tests if taking megestrol acetate (a medicine used to stimulate appetite and help gain weight) can reduce weight loss caused by chemotherapy in people with locally advanced colorectal cancer. It may help you maintain strength and energy during treatment.

Guangzhou, Guangdong

Hear when a new Cachexia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.